Under a new agreement, Third Arc Bio will utilise Adagene’s SAFEbody technology platform to generate masked CD3 T cell engagers against unique tumour associated antigens.   In return, Third Arc Bio will receive rights to research, develop and commercialise two candidate molecules worldwide.   Adagene will receive an upfront payment of $5 million and is eligible to […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!